HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.02290508v1 3/6/1684    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hutchison, C. A. Articles by Cockwell, P. Search for Related Content PubMed PubMed Citation Articles by Hutchison, C. A. Articles by Cockwell, P.

Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney Disease

Colin A. Hutchison^*,, Stephen Harding, Pete Hewins^*, Graham P. Mead^,||, John Townsend, Arthur R. Bradwell^,||, and Paul Cockwell^*,

Departments of ^* Renal Medicine and Cardiology, Queen Elizabeth Hospital, QEMC, The Binding Site Ltd., and Divisions of Medical Sciences and ^|| Immunity and Infection, Medical School, University of Birmingham, Birmingham, United Kingdom

Correspondence: Dr. Colin A. Hutchison, Renal Unit, University Hospital Birmingham, Birmingham, B152TH, UK. Phone: +44-7723917870; Fax: +44-1214306482; E-mail: cah692{at}bham.ac.uk

Background and objectives: Monoclonal free light chains (FLC) frequently cause kidney disease in patients with plasma cell dyscrasias. Polyclonal FLC, however, have not been assessed in patients with chronic kidney disease (CKD) yet could potentially play an important pathologic role. This study describes for the first time polyclonal FLC in patients with CKD.

Design, setting, participants, & measurements: A sensitive, quantitative immunoassay was used to analyze serum and urinary polyclonal FLC in 688 patients with CKD of various causes.

Results: Serum and FLC concentrations increased progressively with CKD stage (both P < 0.001) and strongly correlated with markers of renal function, including cystatin-C (: R = 0.8, P < 0.01; and : R = 0.79, P < 0.01). Urinary FLC concentrations varied significantly between disease groups (: P < 0.001; : P < 0.005) and also rose significantly with increasing CKD stage (both FLC P < 0.0001). Urinary FLC concentrations were positively correlated with their corresponding serum concentration (: R = 0.63; : R = 0.65; both P < 0.001) and urinary albumin creatinine ratio (: R = 0.58; : R = 0.65; both P < 0.001). The proportion of patients with abnormally high urinary FLC concentrations rose with both the CKD stage and the severity of albuminuria.

Conclusions: This study demonstrates significant abnormalities of serum and urinary polyclonal FLC in patients with CKD. These data provide the basis for studies that assess the contribution of polyclonal FLC to progressive renal injury and systemic inflammation in patients with kidney disease.

This article has been cited by other articles:

				R. L. Comenzo How I treat amyloidosis Blood, October 8, 2009; 114(15): 3147 - 3157. [Abstract] [Full Text] [PDF]

				J. A. Katzmann, R. A. Kyle, J. Benson, D. R. Larson, M. R. Snyder, J. A. Lust, S. V. Rajkumar, and A. Dispenzieri Screening Panels for Detection of Monoclonal Gammopathies Clin. Chem., August 1, 2009; 55(8): 1517 - 1522. [Abstract] [Full Text] [PDF]

				E. J.D. Robson, J. Taylor, C. Beardsmore, S. Basu, G. Mead, and T. Lovatt Utility of Serum Free Light Chain Analysis When Screening for Lymphoproliferative Disorders: The Experience at a District General Hospital in the United Kingdom Lab Med, June 1, 2009; 40(6): 325 - 329. [Full Text] [PDF]

				D. Siegel, E. Bilotti, and K. H. van Hoeven Serum Free Light Chain Analysis for Diagnosis, Monitoring, and Prognosis of Monoclonal Gammopathies Lab Med, June 1, 2009; 40(6): 363 - 366. [Abstract] [Full Text] [PDF]